biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > The next two weeks:

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Apr 28, 2023 1:28pm

345 Views

Post# 35419572

The next two weeks:

BTI runs out of cash runway based on expectations in the last news release.
Protalix potentially has European approval for Fabry.
US FDA PDUFA date is May 9.

The next two weeks is pretty much a defining moment for Chiesi's LSD franchise.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale